Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with ...

A gentler treatment for children whose leukemia has come back could boost survival and quality of life, a study led by a UCL academic has found.

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate ...

The ORR was 69% (95% CI, 61-76) in the zanubrutinib arm and 46% (95% CI, 34-58) in the obinutuzumab monotherapy arm. The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Impact of ...

Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ...

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.